^
Association details:
| Biomarker: | PD-L1 amplification + PD-L2 amplification + TMB-H |
|---|---|
| Cancer: | Anal Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification
Published date:
05/24/2021
Excerpt:
...44-year-old female...treated for metastatic anal squamous cell carcinoma with second-line pembrolizumab and has achieved a sustained partial response after a follow-up of 13 months....Comprehensive genomic profiling was remarkable for PD-L1 and PD-L2 amplification and a high tumor mutational burden (19 mutations per megabase)....first report to correlate PD-L1 and PD-L2 amplification with good outcomes of immune checkpoint inhibition in metastatic anal squamous cell carcinoma.
DOI:
https://doi.org/10.1016/j.clcc.2021.05.008
